Unlocking the Potential of ATP1A1 as a Drug Target and Biomarker for Molecular Medicine

Target Name: ATP1A1

NCBI ID: G476

ATP1A1

Unlocking the Potential of ATP1A1 as a Drug Target and Biomarker for Molecular Medicine

Introduction

ATP (adenosine triphosphate) is a crucial molecule in cell signaling and energy transfer. The Na,K-ATPase enzyme, also known as ATP-dependent ATPase alpha-A (ATP1A1), is a key player in this process, catalyzing the conversion of ADP (adenosine diphosphate) to ATP with high affinity and specificity. This enzyme has been implicated in various physiological processes, including muscle contractions, heart rate, and cell signaling. In this article, we will explore the potential of ATP1A1 as a drug target and biomarker in molecular medicine.

The Importance of ATP1A1 in Cell signaling

ATP is the primary currency of cell signaling, enabling the rapid transfer of energy and information between cells. The Na,K-ATPase enzyme plays a central role in this process, as it catalyzes the conversion of ADP to ATP, which is the direct energy source for many cellular functions. This reaction is reversible, and the ATPase enzyme can also catalyze the reverse reaction, converting ATP to ADP and releasing energy as a proton gradient.

ATP1A1 is involved in various cellular processes that require rapid and efficient energy transfer, including muscle contractions, heart rate, and intracellular signaling. For instance, ATP1A1 is critical in muscle protein synthesis, as it provides the energy for the muscle fibers to contract during physical activity. In addition, ATP1A1 is involved in the regulation of heart rate and cardiac contractions.

ATP1A1 as a Potential Drug Target

The identification of ATP1A1 as a potential drug target is based on several factors. Firstly, the enzyme has been implicated in various diseases, including heart failure, hypertension, and muscle-related disorders. Secondly, several compounds have been shown to inhibit ATP1A1 activity, leading to potential therapeutic benefits.

One of the most promising compounds is NL-TXN2, a inhibitor of the ATPase enzyme. NL-TXN2 has been shown to decrease muscle contractions and improve muscle function in mice with muscle-related disorders. This suggests that NL-TXN2 could be a useful agent for the treatment of such disorders.

ATP1A1 as a Biomarker

ATP1A1 has also been suggested as a potential biomarker for various diseases. For instance, the levels of ATP1A1 have been shown to be elevated in the hearts of dogs with heart failure, which could be an indicator of the severity of the disease. Additionally, some studies have shown that ATP1A1 levels are decreased in the hearts of mice with hypertension, which could be an indicator of the severity of the disease.

Conclusion

In conclusion, ATP1A1 is a crucial enzyme involved in various cellular processes that require energy transfer. The identification of ATP1A1 as a potential drug target and biomarker suggests that it may be a promising area for future research in molecular medicine. Further studies are needed to fully understand the therapeutic potential of ATP1A1 and its potential as a drug.

Protein Name: ATPase Na+/K+ Transporting Subunit Alpha 1

Functions: This is the catalytic component of the active enzyme, which catalyzes the hydrolysis of ATP coupled with the exchange of sodium and potassium ions across the plasma membrane. This action creates the electrochemical gradient of sodium and potassium ions, providing the energy for active transport of various nutrients

The "ATP1A1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ATP1A1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets